Topically Significant

Cannabinoids are currently used to reduce nausea and vomiting during chemotherapy, to improve appetite in people with HIV/AIDS, to treat epilepsy, and to address chronic pain and muscle spasms (among other uses). Cannabinoids are also currently in various stages of clinical trials to treat sclerosis, lupus, schizophrenia, among a variety of other disorders.   Below, explore the several ways that the Z-pod™ platform technology can confer an advantage to the use of cannabinoids to treat maladies.

Beauty Products

Patchless Patch™: A sustained-release topical mode of application has significant potential to help treat certain disorders.  Zylö has demonstrated extended release of CBD specifically and believe that its ZBD™ offering—a CBD Patchless Patch™—offers significant performance advantages 

Targeting: CBD holds considerable promise for the treatment of acne and other conditions that involve the pores and/or follicles.  The Z-pods™ lodge deep into human pores/follicles and persist there, slowly releasing CBD over an extended period of time.

Bioavailability: The challenge of achieving topical bioavailability of cannabinoids is well-known. Zylö has demonstrated that cannabinoid-loaded Z-pods™ reduce the size and severity of skin lesions associated with lupus, suggesting that the Z-pod™ technology enhances topical bioavailability in a significant and meaningful way.